Iceland· IS-EU/1/16/1154/001-002
Vemlidy
A tenofovir alafenamide product containing tenofovirum alafenamidum inn fúmarat, registered in Iceland by Gilead Sciences Ireland UC*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Tenofovir alafenamide is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AF13 (tenofovir alafenamide), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Tenofovir alafenamide · ATC J05AF13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tenofovir alafenamide costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tenofovir alafenamide · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.29
- IT Italy$18.37
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Tenofovirum alafenamidum INN fúmarat
- Manufacturer
- Gilead Sciences Ireland UC*
- Country
- Iceland (IS)
- ATC code
- J05AF13
- ATC class
- Tenofovir alafenamide
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean06991230 stk x1 þpakkiISK 72709
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tenofovir alafenamide in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVemlidy2care4 ApS
- NorwayVemlidyGilead Sciences Ireland UC
- CzechiaVEMLIDYGilead Sciences Ireland UC, Carrigtohill
- IrelandVemlidy 25 mg film-coated tabletsGilead Sciences Ireland UC
- NetherlandsTenofoviralafenamide Devatis 25 mg, filmomhulde tablettenDevatis GmbH
- PolandVemlidyGilead Sciences Ireland UC
- BelgiumVemlidy 25 mgGilead Sciences Ireland UC
- SwedenVemlidy 25 mg Filmdragerad tablettGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Germany · Tenofoviralafenamid Devatis
- Liechtenstein · Vemlidy
- Netherlands · Tenofoviralafenamide Devatis
- Norway · Vemlidy
- Portugal · Tenofovir Alafenamida Humanis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c120edd9-bf40-4601-b3e5-f88e633a548f GET /v1/drugs/c120edd9-bf40-4601-b3e5-f88e633a548f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "J05AF13",
"marketed": true,
"strength": "25 mg",
"ma_number": "EU/1/16/1154/001-002",
"substance": "Tenofovirum alafenamidum INN fúmarat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í smitsjúkdómum, meltingarfærasjúkdómum, smitsjúkdómum barna og meltingarfærasjúkdómum barna.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42744"
}See everything about tenofovir alafenamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.